RT Generic
T1 Real Life With Tezacaftor and Ivacaftor in Adult Patients With Cystic Fibrosis: Spanish
A1 Carrasco-Hernandez, Laura
A1 Giron-Moreno, Rosa M.
A1 Pelaez, Adrian
A1 Gomez-Bonilla, Ainhoa
A1 Gomez-Crespo, Beatriz
A1 Diab-Caceres, Layla
A1 Tejedor-Ortiz, Ma Teresa
A1 Garcia-Clemente, Marta
A1 Solis-Garcia, Marta
A1 Gonzalez-Torres, Lucia
A1 Blanco-Aparicio, Marina
A1 Olveira-Fuster, Casilda
A1 Giron-Fernandez, Ma Victoria
A1 Zamarron-de-Lucas, Esther
A1 Prados-Sanchez, Concha
A1 Quintana-Gallego, Esther
K1 Cystic Fibrosis
K1 Cystic Fibrosis Transmembrane Conductance Regulator
K1 Tezacaftor
K1 Ivacaftor
AB Cystic fibrosis (CF) is an autosomal recessive, multisystem genetic disease that mainly affects the exocrine glands due to the absence or alteration of a protein, called cystic fibrosis transmembrane conductance regulator (CFTR).1,2 Until a decade ago, the only treatments available tried to control or prevent the symptoms that were occurring. However, in recent years a line of treatments that improve the functionality of the altered protein has been developed, called CFTR modulators. Tezacaftor–ivacaftor (TEZ/IVA) is modulator of CFTR, indicated in a combined administration regimen for the treatment of CF patients ≥ 6 years, homozygous or heterozygous for the F508del mutation with residual function mutations.3 This drug has been available in Spain since October 1, 2019.
PB Elsevier
SN 0300-2896
YR 2022
FD 2022-09-01
LK http://hdl.handle.net/10668/22018
UL http://hdl.handle.net/10668/22018
LA en
NO Carrasco Hernández L, Girón Moreno RM, Peláez A, Gómez Bonilla A, Gómez Crespo B, et al. Real Life With Tezacaftor and Ivacaftor in Adult Patients With Cystic Fibrosis: Spanish Multicenter Study. Arch Bronconeumol. 2022 Sep;58(9):672-674. English, Spanish
DS RISalud
RD Sep 30, 2025